

## WHITE PAPER

# Ophthalmic Artery Doppler: Technique and Clinical Applications

**Dr. Thomas Hanton<sup>1,2</sup>,**  
**Prof. Asma Khalil<sup>1,3</sup>**

1 Fetal Medicine Unit, Department of Obstetrics and Gynaecology, St George's University Hospital NHS Foundation Trust, City St George's University of London, UK

2 Division of Experimental Medicine in Cambridge, University of Cambridge

3 Fetal Medicine Unit, Liverpool Women's Hospital, University of Liverpool, Liverpool, UK

## Introduction

Globally, hypertensive disorders of pregnancy (HDP) complicate approximately 10% of pregnancies and are a leading cause of maternal and perinatal morbidity and mortality.<sup>1,2</sup> In the UK, most hospitals rely on assessing risk factors at the booking visit to identify patients at increased risk of developing preeclampsia. Routine antenatal visits are used to monitor blood pressure and perform urinalysis to identify women who have manifested HDP. The UK National Screening Committee does not yet recommend screening for preeclampsia.<sup>3</sup> Despite this, there is a growing interest in early prediction and prevention of HDP, particularly preeclampsia, through multivariable prediction algorithms and artificial intelligence (AI).<sup>4</sup> These include maternal risk factors, blood pressure, ultrasound markers (e.g. uterine artery Doppler), and biochemical tests (e.g. placental growth factor).


This report serves as a foundational white paper for integrating ophthalmic artery (OA) Doppler into routine obstetric assessment. OA Doppler provides an easy-to-assess surrogate for intracranial and systemic haemodynamic status.

## Ophthalmic artery


The OA arises from the internal carotid artery as it emerges from the cavernous sinus. It enters the orbit through the optic canal, passing inferolateral to the optic nerve before crossing inferiorly to run medial to the optic nerve (Figure 1). Figures 1 and 2 show the Doppler velocimetry of the OA waveform using pulse-wave Doppler. The following features are presented: first systolic peak (PSV1), second systolic peak (PSV2), dicrotic notch, and the end diastolic velocity (EDV). The first systolic peak is formed by direct transmission from cardiac systole following the ejection of blood flow from the left ventricle into the arterial tree and up into the cranial circulation. The second systolic peak is formed by the reflection of the pulse from cardiac systole into the peripheral vasculature, back towards the heart, and its diversion into the cranial circulation at the level of the aortic arch.

The first systolic peak, therefore, provides a measure predominantly influenced by cardiac output, whereas the second systolic peak provides a measure predominantly influenced by peripheral arterial resistance. Assessing these markers together in the OA PSV-ratio allows the assessment of both cardiac output and peripheral resistance-driven maternal haemodynamics.

## Anatomic Course of the Ophthalmic Artery and Key Features of Its Doppler Waveform



**Figure 1.** Anatomic course of the ophthalmic artery and key features of its Doppler waveform



**Figure 2.** Ophthalmic artery pulse-wave Doppler waveform showing key features of the Doppler waveform

## Ophthalmic artery Doppler

OA Doppler is a promising biomarker for the prediction of preeclampsia. It is easily obtained, cost-effective, reproducible and gives us an insight into the maternal cerebral haemodynamic adaptation. The key Doppler indices for pre-eclampsia prediction include the PSV ratio and pulsatility index (PI). OA Doppler is especially useful in improving the prediction of preterm preeclampsia in the second trimester.<sup>5</sup> This may be especially valuable in low-resource settings where preterm preeclampsia represents a significant burden of maternal morbidity and where serum biomarkers may be unaffordable and uterine artery Doppler may be inaccessible.

Beyond predicting preeclampsia, OA Doppler has been used in stratifying preeclampsia severity and in postnatal monitoring. In hospitalised patients with preeclampsia, PSV2 has been used to stratify women who will have an adverse outcome, although this comes with a high false positive rate.<sup>6</sup> Vaz de Melo et al. in their systematic review and meta-analysis, describe the use of OA Doppler parameters, in the second and third trimesters to stratify between mild and severe preeclampsia<sup>7</sup>. In postnatal monitoring, PSV2 may be helpful in monitoring the long-term cardiac effects of hypertensive disorders of pregnancy.<sup>8,9</sup>

**Table 1.** First trimester prediction of preeclampsia (Gana et al)<sup>10</sup>

| Screening model                                       | Detection Rate (Preterm PE) at 10% false positive rate | Detection Rate (Late PE) at 10% false positive rate |
|---|--|---|
| Maternal factors                                      | 46.3%  | 36.1%   |
| Maternal factors + MAP                                | 57.3%  | 44.5%   |
| Maternal factors + MAP + UtA PI                       | 65.9%  | 44.8%   |
| Maternal factors + MAP + UtA PI + PlGF                | 74.6%  | 46.7%   |
| Maternal factors + MAP + OA PSV ratio                 | 63.8%  | 44.6%   |
| Maternal factors + MAP + OA PSV ratio + UtA-PI + PlGF | 76.7%  | 47.0%   |

Gana et al assess the use of Ophthalmic artery (OA) Doppler in the first trimester to predict the development of preterm and late preeclampsia (Table 1). They showed that a traditional screening approach simply assessing maternal factors has a poor detection rate both for preterm and late preeclampsia. On addition of maternal mean arterial blood pressure (MAP) this detection rate improves for preterm preeclampsia to 57.3%, but with the addition of uterine artery pulsatility index (UtA PI), and biochemical markers of placental hypoperfusion (placental growth restriction (PlGF)), the detection rate significantly increases to 74.6%. The addition of PSV ratio improves the detection rate to 76.7%. The PSV ratio does not significantly improve the prediction of term preeclampsia.

**Table 2.** Second trimester prediction of preeclampsia (Sapantzoglou et al)<sup>11</sup>

| Screening model  | Detection Rate (Preterm PE) at 10% false positive rate | Detection Rate (Late PE) at 10% false positive rate |
|--|--|---|
| Maternal factors   | 55.6%  | 31.0%   |
| Maternal factors + MAP   | 61.1%  | 51.7%   |
| Maternal factors + MAP + UtA PI                                | 66.7%  | 41.1%   |
| Maternal factors + MAP + UtA PI + PlGF                         | 72.2%  | 43.1%   |
| Maternal factors + MAP + OA PSV ratio                          | 77.8%  | 53.4%   |
| Maternal factors + MAP + OA PSV ratio + UtA-PI + sFlt-1 + PlGF | 88.9%  | 48.3%   |

Sapantzoglou et al look at OA Doppler in the prediction of both preterm and late preeclampsia in the second trimester (Table 2). Compared to the first trimester the detection rate of preterm preeclampsia is generally improved. When combined with maternal factors, biochemical markers and uterine artery doppler, the detection rate at a 10% false positive rate is almost 90%. OA Doppler adds a significant improvement in the detection rate. Furthermore, OA Doppler also adds an improvement in the detection rate of late preeclampsia from 51.7% to 53.4% compared to maternal factors and blood pressure alone.

**Table 3.** Third trimester prediction of preeclampsia (Sarno et al)<sup>12</sup>

| Screening model                 | Detection Rate (Preeclampsia - Delivery at any stage) at 10% false positive rate | Detection Rate (Preeclampsia - Delivery at <3 weeks) at 10% false positive rate |
|---------------------------------|--|---|
| Maternal factors                | 25.0%  | 31.6%   |
| Maternal factors + OA PSV ratio | 50.0%  | 57.9%   |

Sarno et al were not looking to predict early and late preeclampsia as the screening in their study took place in the third trimester at 35–37 weeks' gestation (Table 3). Instead, they looked at the detection rate of preeclampsia and the detection rate of preeclampsia with delivery in less than 3 weeks' time. They found that OA Doppler doubles the detection rate of pre-eclampsia compared to maternal factors alone (25% to 50%) and improved the detection rate of preeclampsia with delivery <3 weeks to 57.9%.

## Core measurement indices

### Measured Indices

- First systolic peak velocity = PSV1
- Second systolic peak velocity = PSV 2
- End diastolic velocity = EDV

### Calculated Indices

- Resistance Index =  $(PSV1-EDV) / (PSV1)$
- Pulsatility Index =  $(PSV1-EDV) / (\text{mean velocity})$
- Peak systolic ratio (PSV ratio) =  $PSV2 / PSV1$


## Recording of the ophthalmic artery Doppler waveform

A trained sonographer should place the linear LM2-18 probe (Samsung Medison Co., Ltd., Seoul, Republic of Korea) on the closed upper eyelid of a patient lying supine (who has been lying supine for 5 minutes) (Figure 3). This high frequency linear probe has several features that help optimise ophthalmic artery Doppler acquisition. The high frequency allows clear visualisation of the hypoechoic optic nerve against the retrobulbar fat. The linear matrix array improves slice thickness, reducing spectral broadening and background noise in the pulse-wave Doppler. No pressure should be applied to the globe. Colour flow should be used to identify the ophthalmic artery superior and medial to the optic nerve seen as a hypoechoic band. Pulsed wave Doppler should be used to measure the blood flow waveform with the 2mm sample gate placed approximately 10-15mm from the posterior side of the globe. The pulsed wave Doppler should be optimised by angle correcting up to 20 degrees (Figure 4). At least one measurement should be taken from each eye (Box 1).<sup>13</sup>

The waveform can be analysed through automated and manual acquisition of key indices. This involves using the auto trace function to trace the waveform and manually selecting 2<sup>nd</sup> PSV and marking the position of the 2<sup>nd</sup> PSV within the Doppler trace. Alternatively, key parts of the Doppler trace can be marked manually. The software will then automatically calculate the core measurement indices (Figure 5 & Figure 6).



**Figure 3.** Probe position on the eyelid to capture the ophthalmic artery waveform



**Figure 4.** a) Left ophthalmic artery lying superior and medial to the optic nerve and b) angle correction of 17 degrees




Figure 5. Doppler waveform with manual placement of first PS, second PS and EDV with calculation of the PS Ratio and RI




Figure 6. Doppler waveform with automatic tracing of the waveform and auto calculation PS Ratio, first PS, EDV, PI and RI

## Transducer

**Frequency:** 2-18 MHz linear probe

**Mode:** Pulsed-wave Doppler

## Machine settings

**Wall filter:** 50-100 Hz

**PRF:** 2-5 kHz (avoids aliasing while preserving sensitivity)

**Gain:** Low to moderate, just enough to visualise waveform

**Angle:** Optimal insonation angle is 0-20°

## Acquisition protocol for pregnant patients

**Patient position:** Supine or semi-recumbent

### Preparation:

Closed eyelid technique, apply minimal gel. Maintain gentle probe pressure to avoid altering ocular pressure

### Locate the artery:

Position the probe on the medial upper eyelid

Identify optic nerve hypo echogenicity in B-mode; ophthalmic artery lies medial and superior

### Capture waveform:

Align Doppler angle as close to zero as possible

Record  $\geq 3$  consistent waveforms from each eye

### Box 1. Assessment of the ophthalmic artery Doppler

## Interpretation of Doppler parameters

### Peak Systolic Velocity (PSV)

Reflects systolic flow driven by cardiac output

### End-Diastolic Velocity (EDV)

Sensitive to downstream (intracranial/orbital) resistance

### Resistance Index (RI)

$$RI = (PSV - EDV) / PSV$$

### Pulsatility Index (PI)

$$PI = (PSV - EDV) / \text{mean velocity}$$

### Box 2. Interpretation of ophthalmic artery Doppler parameters

## Safety and compliance

The HERA Z20 (Samsung Medison Co., Ltd., Seoul, Republic of Korea) with the LM2-18 probe has a specific ophthalmic artery preset which can be quickly recalled using the QuickPreset menu. The preset is configured to comply with stringent international safety guidelines, such as the FDA's recommendation for ophthalmic exams. These ensure that the acquisition of the ophthalmic artery pulse wave Doppler is captured with low thermal and mechanical indices<sup>12</sup> (Top right corner of Figure 4a, 5 and 6). These are prominently displayed during the scan and should be minimised due to the sensitivity of the optic tissue. By minimising these indices and because of the short time needed to acquire the measurements, the radiation safety ALARA principle (as low as reasonably achievable), can be maintained (Box 3).

### Safety considerations in pregnancy

Orbital ultrasound has established safety parameters:

#### **Mechanical Index (MI)**

Maintain MI <0.23 to prevent acoustic radiation pressure effects on the lens and retina

#### **Thermal Index (TI)**

Maintain TI <1.0, ideally <0.5, especially with prolonged insonation

#### **Exposure time**

Limit Doppler sampling for each eye to <30 seconds

#### **Gentle probe pressure**

Excessive pressure can reduce ocular perfusion and distort readings

**Box 3.** Safety considerations in pregnancy

## Conclusion

The growing evidence on the use of ophthalmic artery Doppler in predicting preeclampsia will allow us to move toward more precision-based screening and away from traditional risk-based screening, which is less resource-efficient and less personalised. Ensuring maternal cardiovascular health is at the forefront of prenatal screening will not only help us understand the risk of pregnancy complications but may also help us understand long-term cardiovascular health.

## References

1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health* 2014;2:e323–33.
2. Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. *Lancet* 2006;367:1066–74.
3. UK National Screening Committee. Antenatal screening programme - Pre-eclampsia. <https://view-health-screening-recommendations.service.gov.uk/pre-eclampsia/>. Accessed 1st February 2026.
4. Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. *Am J Obstet Gynecol* 2022;226:S1108–19.
5. Arkorful J, Browne JL, Adu-Bonsaffoh K, et al. Predictive accuracy of ophthalmic artery Doppler for pre-eclampsia: a systematic review. *BMJ Open*. 2025 Jun 27;15(6):e094348.
6. Naves WU, Moreira RA, Nascimento Pereira Monteiro V, et al. The use of Doppler velocimetry of the ophthalmic artery and the fullPIERS model to predict adverse outcomes in hospitalized pregnant women with preeclampsia: a prospective cohort study. *J Matern Fetal Neonatal Med*. 2025 Dec;38(1):2526112.
7. de Melo PFMV, Roeber L, Mendonça TMS, et al. Ophthalmic artery Doppler in the complementary diagnosis of preeclampsia: a systematic review and meta-analysis. *BMC Pregnancy Childbirth*. 2023 May 12;23(1):343.
8. Dimopoulou S, Neculcea D, Papastefanou I, et al. Long-term cardiovascular assessment of women with previous pregnancy complicated by hypertensive disorder. *Ultrasound Obstet Gynecol*. 2024 Sep;64(3):308-313.
9. Alves Borges JH, Goes DA, de Araújo LB, et al. Prospective study of the hemodynamic behavior of ophthalmic arteries in postpartum preeclamptic women: A doppler evaluation. *Hypertens Pregnancy*. 2016;35(1):100-11.
10. Gana N, Sarno M, Vieira N, et al. Ophthalmic artery Doppler at 11-13 weeks' gestation in prediction of pre-eclampsia. *Ultrasound Obstet Gynecol*. 2022 Jun;59(6):731-736.
11. Sapantzoglou I, Wright A, Arozena MG, et al. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 19-23 weeks' gestation. *Ultrasound Obstet Gynecol*. 2021 Jan;57(1):75-83. doi: 10.1002/uog.23528. Epub 2020 Dec 4. Erratum in: *Ultrasound Obstet Gynecol*. 2022 Mar;59(3):407.
12. Sarno M, Wright A, Vieira N, et al. Ophthalmic artery Doppler in prediction of pre-eclampsia at 35-37 weeks' gestation. *Ultrasound Obstet Gynecol*. 2020 Nov;56(5):717-724.
13. The Safety Group of the British Medical Ultrasound Society. Guidelines for the safe use of diagnostic ultrasound equipment. *Ultrasound*. 2010;18:52–9.

## Disclaimer

- \* The features mentioned in this document may not be commercially available in all countries and may contain more detailed information than officially approved. Due to regulatory reasons, their future availability cannot be guaranteed.
- \* Do not distribute this document to customers unless relevant regulatory and legal affairs officers approve such distribution.
- \* Images may have been cropped to better visualize their pathology.
- \* This study was funded by Samsung Medison to aid customers in their understanding.
- \* The results reflect the experience of a single user at a single site, and may not be representative of results that may be obtained in other settings. Healthcare professionals should rely on their own professional judgment and experience when interpreting these results and making clinical decision.



Scan QR code or visit  
[samsunghealthcare.com](https://samsunghealthcare.com)  
to learn more

---

**SAMSUNG MEDISON CO., LTD.**

©2026 Samsung Medison All Rights Reserved.

Samsung Medison reserves the right to modify any design, packaging, specifications and features shown herein, without prior notice or obligation